1-20 of 250
Moshe Talpaz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T315I-Mutated CML-CP: Final Analysis from a Phase 1 Trial

Jorge E. Cortes, Delphine Rea, Michael J. Mauro, Andreas Hochhaus, Dong-Wook Kim, Koji Sasaki, Fabian Lang, Michael C. Heinrich, Massimo Breccia, Michael W. Deininger, Yeow Tee Goh, Jeroen J.W.M. Janssen, Moshe Talpaz, Valle Gomez G De Soria, Philipp le Coutre, Francois-Xavier Mahon, Daniel Deangelo, Shruti Kapoor, Gessami Sanchez-Olle, Meng Cao, Nithya Agrawal, Timothy P Hughes
Journal: Blood
Blood (2024) 144 (Supplement 1): 1765.
https://doi.org/10.1182/blood-2024-209537
Published: 2024
Journal Articles

Efficacy and Safety of Fedratinib in Patients with Myelofibrosis and Low Baseline Platelet Counts in the Phase 3 Randomized FREEDOM2 Trial

Haifa Kathrin Al-Ali, Claire Harrison, Ruben Mesa, Moshe Talpaz, Blanca Xicoy, Francesco Passamonti, Alessandro Vannucchi, Patrick Brown, Christopher Hernandez, Jia Wang, Jun He, Jean-Jacques Kiladjian
Journal: Blood
Blood (2024) 144 (Supplement 1): 482.
https://doi.org/10.1182/blood-2024-193645
Published: 2024
Journal Articles

Inhibition of Endoplasmic Reticulum Associated Degradation Is Cytotoxic to Relapsed Refractory Multiple Myeloma through Altered Proapoptotic Signaling

Erin M Kropp, Sho Matono, Aaron Robida, Malathi Kandarpa, Olivia Wang, Andrew Alt, Moshe Talpaz, Matthew Pianko, Qing Li
Journal: Blood
Blood (2024) 144 (Supplement 1): 3264.
https://doi.org/10.1182/blood-2024-203713
Published: 2024
Journal Articles

Phase 2 Study Using Minimal Residual Disease-Driven Adaptive Strategy in Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy - First Report from the Maestro Trial

J Christine Ye, Philip Boonstra, Erica L. Campagnaro, Matthew Pianko, Andrew Kin, Larry D Anderson, Jr., Brea Lipe, Moshe Talpaz, Jeffrey A. Zonder
Journal: Blood
Blood (2024) 144 (Supplement 1): 3379.
https://doi.org/10.1182/blood-2024-209505
Published: 2024
Journal Articles

Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor-Naïve Patients with Myelofibrosis

John O. Mascarenhas, Sebastian Grosicki, Dominik Chraniuk, Elisabetta Abruzzese, Prithviraj Bose, Aaron T. Gerds, Alessandro M. Vannucchi, Francesca Palandri, Sung-Eun Lee, Vikas Gupta, Alessandro Lucchesi, Stephen Oh, Andrew T. Kuykendall, Andrea Patriarca, Alberto Alvarez-Larran, Ruben Mesa, Jean-Jacques Kiladjian, Moshe Talpaz, Morgan Harris, Sarah-Katharina Kays, Qing Li, Barbara Brown, Anna-Maria Jegg, Claire Harrison, Raajit Rampal
Journal: Blood
Blood (2024) 144 (Supplement 1): 3178.
https://doi.org/10.1182/blood-2024-193193
Published: 2024
Journal Articles

A Phase 1/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis

John O. Mascarenhas, Raajit Rampal, Firas El Chaer, Vikas Gupta, Kazuya Shimoda, Jean-Jacques Kiladjian, Francesco Passamonti, Prithviraj Bose, Joseph M. Scandura, Ruben Mesa, Lindsay A.M. Rein, Junichiro Yuda, David M Ross, Timothy Devos, Moshe Talpaz, Ronald Hoffman, Sujan Kabir, Zhonggai Li, Jason M. Foulks, Karen Ansaldo, Masataka Seki, Vishnu Peddagali, Jatin Shah, Claire Harrison
Journal: Blood
Blood (2024) 144 (Supplement 1): 6629.
https://doi.org/10.1182/blood-2024-200268
Published: 2024
Journal Articles

Biomarkers of Renal Health in Patients (pts) Treated with Fedratinib in the FREEDOM and FREEDOM2 Trials

Vikas Gupta, Yizhe Chen, Patrick Brown, Danny Jeyaraju, Moshe Talpaz, Ruben Mesa, Richard Pilot, Christopher Hernandez, Jia Wang, Jean-Jacques Kiladjian, Alessandro Vannucchi, Claire Harrison
Journal: Blood
Blood (2024) 144 (Supplement 1): 6623.
https://doi.org/10.1182/blood-2024-194223
Published: 2024
Journal Articles

Examining Ras/MAP Kinase Signaling in Primary Myelofibrosis May Yield Insight into the Mechanisms of JAK Inhibitor Resistance and Provide New Therapeutic Targets

Samuel B Reynolds, Malathi Kandarpa, Mark Ribick, Moshe Talpaz, Qing Li
Journal: Blood
Blood (2024) 144 (Supplement 1): 6568.
https://doi.org/10.1182/blood-2024-199399
Published: 2024
Journal Articles

A Phase 1b Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia

Naseema Gangat, James M. Foran, Anna B. Halpern, Raajit Rampal, Prithviraj Bose, Elizabeth O. Hexner, Moshe Talpaz, Laura C. Michaelis, Prioty Islam, Ronan T. Swords, Sima Bhatt, Akshay Buch, Olivia Pelletier, Will Savage, Ayalew Tefferi
Journal: Blood
Blood (2024) 144 (Supplement 1): 657.
https://doi.org/10.1182/blood-2024-203719
Published: 2024
Journal Articles

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

Brief Report
Ayalew Tefferi, Giovanni Barosi, Francesco Passamonti, Juan-Carlos Hernandez-Boluda, Prithviraj Bose, Konstanze Döhner, Martin Ellis, Naseema Gangat, Jacqueline S. Garcia, Heinz Gisslinger, Jason Gotlib, Paola Guglielmelli, Vikas Gupta, Claire Harrison, Elizabeth O. Hexner, Gabriela S. Hobbs, Jean-Jacques Kiladjian, Steffen Koschmieder, Nicolaus Kroger, Andrew T. Kuykendall, Giuseppe G. Loscocco, John Mascarenhas, Lucia Masarova, Ruben Mesa, Barbara Mora, Olatoyosi Odenike, Stephen T. Oh, Animesh Pardanani, Anand Patel, Naveen Pemmaraju, Alessandro Rambaldi, Raajit Rampal, Shireen Sirhan, Natasha Szuber, Moshe Talpaz, Pankit J. Vachhani, Alessandro M. Vannucchi, Tiziano Barbui
Journal: Blood
Blood (2024) 144 (17): 1813–1820.
https://doi.org/10.1182/blood.2024025802
Published: 2024
Journal Articles

With up to 8 Years of Therapy, Asciminib (ASC) Monotherapy Demonstrated Continued Favorable Efficacy, Safety, and Tolerability in Patients (Pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) without the T315I Mutation: Final Results from the Phase 1 X2101 Study

Andreas Hochhaus, Dong-Wook Kim, Jorge Cortes, Koji Sasaki, Michael Mauro, Timothy P Hughes, Massimo Breccia, Moshe Talpaz, Hironobu Minami, Yeow Tee Goh, Daniel J. DeAngelo, Fabian Lang, Michael C. Heinrich, Valle Gomez G De Soria, Philipp le Coutre, Gessami Sanchez-Olle, Jomy Jose, Nathalie Pognan, Shruti Kapoor, Delphine Rea
Journal: Blood
Blood (2023) 142 (Supplement 1): 450.
https://doi.org/10.1182/blood-2023-187322
Published: 2023
Journal Articles

BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study

David Lavie, Vincent Ribrag, Michael Loschi, Costas K. Yannakou, Maan Alwan, Adi Schacham Abulafia, Jesús María Hernández-Rivas, Yulia Volchek, Chun Yew Fong, Massimiliano Bonifacio, Jean-Jacques Kiladjian, Jean-Christophe Ianotto, Valentín García Gutiérrez, Alessandra Tucci, Blanca Xicoy, Haifa Kathrin Al-Ali, Moshe Talpaz, Jonathan M. Gerber, Indu Raman, Ciprian Tomuleasa, Si Tuen Lee-Hoeflich, Sharmila Das, Bin Wu, Qian Zhao, Eunhee Kim, Oriana Esposito, Yu Liu, Zariana Nikolova, Christopher Tehlirian, Shodeinde Coker, Rosa Ayala
Journal: Blood
Blood (2023) 142 (Supplement 1): 623.
https://doi.org/10.1182/blood-2023-179160
Published: 2023
Journal Articles

Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study

Raajit K. Rampal, Sebastian Grosicki, Dominik Chraniuk, Elisabetta Abruzzese, Prithviraj Bose, Aaron T. Gerds, Alessandro M. Vannucchi, Francesca Palandri, Sung-Eun Lee, Vikas Gupta, Alessandro Lucchesi, Stephen T. Oh, Andrew T. Kuykendall, Andrea Patriarca, Alberto Alvarez-Larran, Ruben Mesa, Jean-Jacques Kiladjian, Moshe Talpaz, Morgan Harris, Sarah-Katharina Kays, Anna-Maria Jegg, Qing Li, Barbara Brown, Claire N Harrison, John Mascarenhas
Journal: Blood
Blood (2023) 142 (Supplement 1): 628.
https://doi.org/10.1182/blood-2023-179141
Published: 2023
Journal Articles

MRI Reliably Captures Bone Marrow Metrics in Myelofibrosis

Tanner Robison, Annabel Levinson, Winston Lee, Kristen Marie Pettit, Dariya Malyarenko, Timothy D Johnson, Thomas Chenevert, Brian Ross, Moshe Talpaz, Gary Luker
Journal: Blood
Blood (2023) 142 (Supplement 1): 4556.
https://doi.org/10.1182/blood-2023-189869
Published: 2023
Journal Articles

Efficacy and Safety of Fedratinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Results from the Phase 3 Randomized FREEDOM2 Study

Claire N Harrison, Ruben Mesa, Moshe Talpaz, Haifa Kathrin Al-Ali, Blanca Xicoy, Francesco Passamonti, Francesca Palandri, Giulia Benevolo, Alessandro M. Vannucchi, Clemence Mediavilla, Alessandra Iurlo, InHo Kim, Patrick Brown, Christopher Hernandez, Shelonitda Rose, Jia Wang, Jean-Jacques Kiladjian
Journal: Blood
Blood (2023) 142 (Supplement 1): 3204.
https://doi.org/10.1182/blood-2023-173391
Published: 2023
Journal Articles

Long-Term Results from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Jorge Cortes, Michael Deininger, Elza Lomaia, Beatriz Moiraghi, Soledad Undurraga, Carolina Pavlovsky, Charles Chuah, Tomasz Sacha, Jeffrey H. Lipton, James McCloskey, Andreas Hochhaus, Philippe Rousselot, Gianantonio Rosti, Hugues de Lavallade, Anna Turkina, Lori Maness, Moshe Talpaz, Michael Mauro, Vickie Lu, Alexander Vorog, Jane F Apperley
Journal: Blood
Blood (2023) 142 (Supplement 1): 3164.
https://doi.org/10.1182/blood-2023-178790
Published: 2023
Journal Articles

Ras Activity Is Significantly Elevated in Patients with Primary Myelofibrosis and Is Agnostic to the Presence of RAS and JAK pathwaymutations

Samuel B Reynolds, Malathi Kandarpa, Kristen Marie Pettit, Mark Ribick, Moshe Talpaz, Qing Li
Journal: Blood
Blood (2023) 142 (Supplement 1): 6347.
https://doi.org/10.1182/blood-2023-179503
Published: 2023
Journal Articles

Time without Transfusion Reliance or Anemia Worsening: A Novel Method for Integrating Transfusion Dependence, Anemia, and Survival with Myelofibrosis Therapies Based on the Phase 3 Simplify-1 and Simplify-2 Trials

Ruben A. Mesa, Moshe Talpaz, Flora Mazerolle, Boris Gorsh, Manal M'Hari, Antoine Regnault, Catherine Ellis, Zhaohui Wang, Molly Purser, Tom Liu, Bryan Strouse, Dwaipayan Patnaik
Journal: Blood
Blood (2023) 142 (Supplement 1): 1826.
https://doi.org/10.1182/blood-2023-177784
Published: 2023
Journal Articles

A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses

Kristen M. Pettit, Harinder Gill, Abdulraheem Yacoub, Terrence Bradley, Aaron T. Gerds, Maciej Tatarczuch, Jake Shortt, Natasha Joan Curtin, James M. Rossetti, Kate Burbury, Adam J Mead, Joachim R Göthert, Steffen Koschmieder, Matt Reyer, Benjamin Siranosian, Georges Natsoulis, William S Stevenson, Joanne Ewing, Joseph M. Chacko, Elisa Rumi, Anna B. Halpern, Francesca Palandri, Nicola Vianelli, Francesco Passamonti, Ruben Mesa, Monia Marchetti, Claire Harrison, Alessandro M. Vannucchi, Justin Watts, David M Ross, Moshe Talpaz, Hugh Young Rienhoff, Jr.
Journal: Blood
Blood (2022) 140 (Supplement 1): 9717–9720.
https://doi.org/10.1182/blood-2022-167122
Published: 2022
Journal Articles

Improvement in Individual Symptoms and Total Symptom Score (TSS) and Matching-Adjusted Indirect Comparison (MAIC) Analysis to Compare TSS As a Continuous Endpoint in Patients with Myelofibrosis Treated with Pelabresib in Combination with Ruxolitinib Versus Janus Kinase Inhibitor Monotherapy

Ruben Mesa, Marina Kremyanskaya, Andrea Patriarca, Vikas Gupta, Francesca Palandri, Timothy Devos, Claire Harrison, Raajit K. Rampal, Moshe Talpaz, Alessandro Vannucchi, Andrew Kuykendall, Jean-Jacques Kiladjian, Srdan Verstovsek, Gozde Colak, Debarshi Dey, John Mascarenhas
Journal: Blood
Blood (2022) 140 (Supplement 1): 11056–11059.
https://doi.org/10.1182/blood-2022-159389
Published: 2022